Literature DB >> 15217985

Regulation of interferon-tau (IFN-tau) gene promoters by growth factors that target the Ets-2 composite enhancer: a possible model for maternal control of IFN-tau production by the conceptus during early pregnancy.

Toshihiko Ezashi1, R Michael Roberts.   

Abstract

Expression of interferon-tau gene (IFNT) by conceptuses of cattle and sheep must be in phase with the physiological state of the mother if the pregnancy is to be successful. IFNT has a close-to-consensus AP1 site (-71 to -64), overlapping a binding site for Ets-2 (-79 to -70), the key transcription factor controlling IFNT expression. When a bovine IFNT gene control region-luciferase (luc) construct was transfected into mouse 3T3 fibroblasts in the presence of Ets-2 and oncogenic Ras, luc expression was activated (50- to 100-fold). Mutations in either the activator protein 1 (AP1) site or the Ets-2 site of this construct abolished this effect. Similarly, a mutation of Thr72 of the Ets-2 or the addition of a specific inhibitor for the MAPK signal transduction pathway also markedly reduced expression. IFNT promoter activity was up-regulated in response to colony-stimulating factor-1 in 3T3 cells expressing the colony-stimulating factor-1 receptor c-fms. This response did not occur when the AP1 site or the Ets-2 binding sites were mutated. Nor was the response observed in 3T3 cells expressing an inactive form of c-fms. The experiments indicate that IFNT can be activated by growth factors operating through the Ras/MAPK pathway. The Ets-2 and AP1 binding sites are essential for such effects. The AP1 site, however, is noncanonical and unable to bind either cJun or cFos. These data emphasize the importance of a complex Ets-2 enhancer for expression of IFNT and suggest a means whereby the mother can exert control over conceptus IFN-tau production.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15217985     DOI: 10.1210/en.2004-0606

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

Review 1.  Interferon-tau, a Type 1 interferon involved in maternal recognition of pregnancy.

Authors:  R Michael Roberts
Journal:  Cytokine Growth Factor Rev       Date:  2007-07-27       Impact factor: 7.638

Review 2.  Interferons and the maternal-conceptus dialog in mammals.

Authors:  R Michael Roberts; Yizhen Chen; Toshihiko Ezashi; Angela M Walker
Journal:  Semin Cell Dev Biol       Date:  2007-10-16       Impact factor: 7.727

3.  Expression of bovine interferon-tau variants according to sex and age of conceptuses.

Authors:  Angela M Walker; Koji Kimura; R Michael Roberts
Journal:  Theriogenology       Date:  2009-03-25       Impact factor: 2.740

4.  Combinatorial roles of protein kinase A, Ets2, and 3',5'-cyclic-adenosine monophosphate response element-binding protein-binding protein/p300 in the transcriptional control of interferon-tau expression in a trophoblast cell line.

Authors:  Padmalaya Das; Toshihiko Ezashi; Rangan Gupta; R Michael Roberts
Journal:  Mol Endocrinol       Date:  2007-11-01

Review 5.  Transcriptional control of IFNT expression.

Authors:  Toshihiko Ezashi; Kazuhiko Imakawa
Journal:  Reproduction       Date:  2017-11       Impact factor: 3.906

6.  Ets-2 and C/EBP-beta are important mediators of ovine trophoblast Kunitz domain protein-1 gene expression in trophoblast.

Authors:  Anindita Chakrabarty; Michael R Roberts
Journal:  BMC Mol Biol       Date:  2007-02-27       Impact factor: 2.946

7.  Transcriptional regulation of two conceptus interferon tau genes expressed in Japanese black cattle during peri-implantation period.

Authors:  Toshihiro Sakurai; So Nakagawa; Min-Su Kim; Hanako Bai; Rulan Bai; Junyou Li; Kwan-Sik Min; Atsushi Ideta; Yoshito Aoyagi; Kazuhiko Imakawa
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

8.  Regulation of gene expression in the bovine blastocyst by colony stimulating factor 2.

Authors:  Manabu Ozawa; Miki Sakatani; Kyle B Dobbs; Jasmine Kannampuzha-Francis; Peter J Hansen
Journal:  BMC Res Notes       Date:  2016-04-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.